After a biotech stopped working on a drug to treat Duchenne muscular dystrophy, two families in the US bought the drug to develop it themselves in the hopes of helping family members, reports the Wall Street Journal. Through research foundations, the Secklers and the Wickas paid $500,000 for the drug, called halofuginone, and will pay an additional $500,000.